Initiative to Provide $17.6 Million to 30 U.S. Organizations to Elevate the Work of Community Groups and Provide Support Needed to Strengthen Care for People Aging with HIV

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

Gilead announces new data on the impact of Truvada® (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) on the number of HIV diagnoses in the United States.

A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

MSF said the deals with generic companies meant it was now able to provide a 12-week course of treatment for around $120, against $1,400 to $1,800 available through Gilead and BMS access programs for poorer nations.

Today, The Medicines Patent Pool and Gilead Sciences, Inc reported signing of a licensing agreement on the expansion of access to Bictegravir.

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under ...

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the final ceremony, exposed one of the key conference sponsors, ...